Non-small Cell Lung Cancer Clinical Trial
Official title:
A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). The first part of the study will determine the safe dose for the next part of the study, and will enroll TNBC and NSCLC patients. The second part of the study will test that dose in additional TNBC and NSCLC patients.
Status | Recruiting |
Enrollment | 54 |
Est. completion date | September 2026 |
Est. primary completion date | March 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - = 18 years of age at time of informed consent - Histologically confirmed TNBC or NSCLC that is relapsed or refractory, metastatic or locally advanced and unresectable that is ROR1+ by central laboratory immunohistochemistry (IHC) - Measurable disease including a target lesion and an additional lesion for biopsy - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 - Adequate organ and marrow function - Women of childbearing potential must have a negative pregnancy test at screening - All participants must agree to practice highly effective methods of contraception Exclusion Criteria: - Prior treatment with any adoptive T-cell therapy or anti-ROR1 therapy - Prior solid organ transplantation - Active, untreated brain metastasis or leptomeningeal disease; stable, treated brain involvement by disease is allowed - Untreated or active infection at the time of screening or leukapheresis - HIV-positive, HTLV-1-positive, active acute or chronic HBV or HCV, or active tuberculosis - Impaired cardiac function or clinically significant cardiac disease - Uncontrolled pleural or pericardial effusion - Systemic corticosteroids or other immunosuppressive medications within 14 days of leukapheresis - Required chronic anticoagulation, such as warfarin, low molecular weight heparin, or Factor Xa inhibitors - Pregnant or lactating/nursing women |
Country | Name | City | State |
---|---|---|---|
United States | Montefiore Medical Center | Bronx | New York |
United States | University of Chicago | Chicago | Illinois |
United States | Karmanos Cancer Institute | Detroit | Michigan |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | Mayo Clinic | Jacksonville | Florida |
United States | University of Miami | Miami | Florida |
United States | Froedtert Hospital, Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Sarah Cannon Research Institute and Tennessee Oncology | Nashville | Tennessee |
United States | Yale New Haven Hospital | New Haven | Connecticut |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | University of Oklahoma | Oklahoma City | Oklahoma |
United States | Sidney Kimmel Cancer Center, Jefferson University Hospital | Philadelphia | Pennsylvania |
United States | Oregon Health and Science University Hospital | Portland | Oregon |
United States | Mayo Clinic | Rochester | Minnesota |
United States | University of California, Los Angeles | Santa Monica | California |
United States | Mayo Clinic | Scottsdale | Arizona |
United States | Fred Hutchinson Cancer Research Center | Seattle | Washington |
United States | Georgetown University | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Lyell Immunopharma, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate incidence of dose-limiting toxicities (DLTs) | Incidence of dose-limiting toxicities (DLTs) | Up to 2 years | |
Primary | Evaluate incidence of treatment-emergent adverse events (TEAEs) | Incidence of treatment-emergent adverse events (TEAEs) | Up to 2 years | |
Primary | Evaluate severity of treatment-emergent adverse events (TEAEs) | Severity of treatment-emergent adverse events (TEAEs) | Up to 2 years | |
Primary | Determine recommended Phase 2 Dose (RP2D) | Dose-escalation phase to determine the recommended Phase 2 dose | Up to 2 years | |
Secondary | Evaluate anti-tumor activity of LYL797 based on overall response rate (ORR) by RECIST, version 1.1 | Overall response rate (ORR) by RECIST, version 1.1 | Up to 2 years | |
Secondary | Evaluate anti-tumor activity of LYL797 based on complete response (CR) rate by RECIST, version 1.1 | Complete response (CR) rate by RECIST, version 1.1 | Up to 2 years | |
Secondary | Evaluate duration of response (DOR) | Duration of response (DOR) | Up to 2 years | |
Secondary | Evaluate progression-free survival (PFS) | Progression-free survival (PFS) | Up to 2 years | |
Secondary | Evaluate overall survival (OS) | Overall survival (OS) | Up to 2 years | |
Secondary | Evaluate maximum concentration of LYL797 (Cmax) of LYL797 in peripheral blood (PB) samples | Maximum concentration of LYL797 (Cmax) | Up to 2 years | |
Secondary | Evaluate time to Cmax (Tmax) of LYL797 in peripheral blood (PB) samples | Time to Cmax (Tmax) | Up to 2 years | |
Secondary | Evaluate area under the concentration-time curve (AUC) of LYL797 in the peripheral blood (PB) | Area under the concentration-time curve (AUC) | Up to 2 years | |
Secondary | Evaluate Persistence of LYL797 CAR T cells in peripheral blood samples | Persistence of LYL797 in PB | Up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |